Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VXRT

Vaxart Inc

Mar 26 • 04:00PM ET

0.4645

Dollar change -0.0166
Percentage change -3.45	%

Healthcare • Biotechnology • Australia • NASD

Peers: PFE JNJ BNTX AZN MRNA GSK NVAX CVAC NVCR RLAY

| Held by: VTI VXF ONEQ QQQS PRFZ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	1.04%	Shs Outstand	227.77M	Perf Week	-20.46%
Market Cap	105.88M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	0.00%	Shs Float	225.58M	Perf Month	-6.18%
Income	-66.95M	PEG	-	EPS next Q	-0.10	Inst Own	22.43%	Short Float	5.42%	Perf Quarter	-25.03%
Sales	28.70M	P/S	3.69	EPS this Y	5.05%	Inst Trans	-7.04%	Short Ratio	5.98	Perf Half Y	-44.48%
Book/sh	0.26	P/B	1.80	EPS next Y	-35.64%	ROA	-51.85%	Short Interest	12.23M	Perf Year	-63.13%
Cash/sh	0.23	P/C	2.05	EPS next 5Y	-12.51%	ROE	-114.71%	52W Range	0.45 - 1.41	Perf YTD	-29.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	17.46%	ROI	-89.18%	52W High	-67.06%	Beta	1.51
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	1372.05%	Gross Margin	84.67%	52W Low	3.22%	ATR (14)	0.05
Dividend Ex-Date	Nov 09, 2012	Current Ratio	0.75	EPS Y/Y TTM	39.45%	Oper. Margin	-230.99%	RSI (14)	36.47	Volatility	10.32% 8.90%
Employees	115	Debt/Eq	0.40	Sales Y/Y TTM	288.94%	Profit Margin	-233.27%	Recom	1.00	Target Price	4.67
Option/Short	Yes / Yes	LT Debt/Eq	0.27	EPS Q/Q	53.53%	Payout	-	Rel Volume	0.72	Prev Close	0.48
Sales Surprise	-26.85%	EPS Surprise	60.00%	Sales Q/Q	367.95%	Earnings	Mar 20 AMC	Avg Volume	2.04M	Price	0.46
SMA20	-8.54%	SMA50	-26.28%	SMA200	-34.15%	Trades		Volume	1,465,668	Change	-3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-24	Initiated	Oppenheimer	Outperform	$4
Dec-29-21	Resumed	Jefferies	Buy	$13 → $12
Nov-02-21	Initiated	Cantor Fitzgerald	Overweight	$15
Jun-29-21	Downgrade	B. Riley Securities	Buy → Neutral	$13 → $9
Jun-24-21	Initiated	Jefferies	Buy	$13
Jun-11-21	Initiated	Piper Sandler	Overweight	$18
Aug-12-20	Reiterated	H.C. Wainwright	Buy	$7 → $17
Jul-13-20	Initiated	B. Riley FBR	Buy	$22

Mar-21-25 07:49AM	Q4 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) -9.09%
03:04AM	Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... (GuruFocus.com)
Mar-20-25 06:25PM	Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:15PM	VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire)
10:00AM	Loading…
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	Vaxart FY 2024 Earnings Preview (SeekingAlpha)
Mar-13-25 08:00AM	Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 (GlobeNewswire) -5.96%
Mar-11-25 08:00AM	Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate (GlobeNewswire)
Mar-05-25 04:05PM	Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults (GlobeNewswire)
Jan-28-25 08:00AM	Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors (GlobeNewswire)
Jan-14-25 08:00AM	Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs (GlobeNewswire)
Jan-13-25 07:55PM	Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial (GlobeNewswire) -8.81%
Dec-28-24 09:30AM	Vaxart project agreement change ups funding for oral COVID vaccine candidate (TipRanks)
Dec-02-24 04:01PM	Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
08:00AM	Loading…
Nov-19-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 02:14AM	Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ... (GuruFocus.com) -11.80%
Nov-13-24 05:20PM	VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 08:00AM	Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 (GlobeNewswire)
Oct-24-24 08:00AM	Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need (GlobeNewswire)
Oct-09-24 05:52PM	Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances (GuruFocus.com)
Sep-30-24 04:12PM	Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
Aug-30-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-24 08:00AM	Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia (GlobeNewswire)
Aug-15-24 01:57PM	Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside (Benzinga) +25.66%
Aug-09-24 11:48AM	Q2 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) -7.95%
Aug-08-24 09:59PM	VXRT Stock Earnings: Vaxart Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) +5.74%
05:30PM	VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-02-24 08:00AM	Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8 (GlobeNewswire) -5.95%
Jun-17-24 04:05PM	Vaxart Provides Business Update (GlobeNewswire) -8.25% +30.16%
Jun-14-24 10:06AM	Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering (Benzinga) -23.67%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-13-24 07:07PM	Vaxart Announces $40 Million Underwritten Offering of Common Stock (GlobeNewswire)
04:15PM	Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire)
May-23-24 04:01PM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.46%
May-14-24 01:07PM	Q1 2024 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents) +5.45%
08:20AM	Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:07AM	Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ... (GuruFocus.com)
May-13-24 08:56PM	VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024 (InvestorPlace) +16.31%
04:01PM	Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 08:00AM	Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13 (GlobeNewswire)
Apr-30-24 08:00AM	Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Apr-09-24 04:30PM	Election Year Encore: Can 2020s Top 7 Stock Winners Repeat Their Performance in 2024? (InvestorPlace)
Mar-27-24 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 (GlobeNewswire) +5.74%
Mar-20-24 08:00AM	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.90%
Mar-15-24 01:45PM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:33AM	Q4 2023 Vaxart Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-14-24 08:55PM	VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-07-24 08:00AM	Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 (GlobeNewswire) -7.50%
Mar-06-24 08:00AM	Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director (GlobeNewswire)
Feb-26-24 12:00PM	VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-20-24 09:55AM	VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Feb-05-24 08:00AM	Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge (GlobeNewswire)
Jan-19-24 08:30AM	Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate (GlobeNewswire) -6.59%
Jan-16-24 09:25AM	Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management (GlobeNewswire) +29.41%
09:22AM	Vaxart, Inc. Announces Management Change (GlobeNewswire)
Dec-21-23 08:00AM	Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Nov-03-23 11:47AM	Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.09%
Nov-02-23 06:39PM	Vaxart Inc (VXRT) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:01PM	Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
08:00AM	Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers (GlobeNewswire)
Oct-26-23 08:00AM	Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2 (GlobeNewswire)
Oct-11-23 08:00AM	Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19 (GlobeNewswire)
Sep-21-23 08:00AM	Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-12-23 12:48PM	3 Biotech Blockbusters to Turn $5,000 Into $50,000 (InvestorPlace)
Sep-06-23 04:05PM	Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate (GlobeNewswire) -8.00%
Aug-15-23 01:46PM	Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now (Zacks)
Aug-05-23 06:39AM	Vaxart, Inc. (NASDAQ:VXRT) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:15PM	VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-27-23 08:00AM	Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3 (GlobeNewswire)
Jul-06-23 08:00AM	Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate (GlobeNewswire)
Jun-26-23 04:45PM	Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement (GlobeNewswire) -15.28%
Jun-21-23 04:30PM	Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET (GlobeNewswire) +5.31%
Jun-07-23 09:16AM	Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock (GlobeNewswire) -27.41%
Jun-06-23 04:01PM	Vaxart, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate (GlobeNewswire)
May-31-23 08:00AM	Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET (GlobeNewswire)
07:47AM	Here's Why We're A Bit Worried About Vaxart's (NASDAQ:VXRT) Cash Burn Situation (Simply Wall St.)
May-04-23 04:01PM	Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-28-23 08:00AM	Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4 (GlobeNewswire) +6.01%
Apr-24-23 05:30AM	These 2 Stocks Carry a Lot of Risk, but Their Upside Is Huge (Motley Fool)
Mar-29-23 08:00AM	Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6 (GlobeNewswire) +6.70%
Mar-18-23 02:56AM	Vaxart, Inc. (NASDAQ:VXRT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 08:00AM	Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus (GlobeNewswire)
Mar-15-23 04:01PM	Vaxart Provides Business Update and Full Year 2022 Financial Results (GlobeNewswire)
Mar-08-23 04:05PM	Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15 (GlobeNewswire) -8.66%
Feb-14-23 08:00AM	Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate (GlobeNewswire)
Jan-18-23 09:00AM	Covid Isnt Going Away. New Drugs Are Coming. (Barrons.com)
Jan-09-23 08:27AM	Profound Medical (PROF) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
Dec-19-22 08:00AM	Vaxart Names Phillip Lee as Chief Financial Officer (GlobeNewswire) -14.51%
Dec-01-22 08:00AM	Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers (GlobeNewswire)
Nov-22-22 08:30AM	Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29 (GlobeNewswire)
Nov-11-22 05:47AM	Vaxart Third Quarter 2022 Earnings: US$0.23 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) +7.10%
Nov-08-22 05:45PM	VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.35%

Biota Holdings Limited is an Australian company engaged in anti-infective drug discovery and development, and its commercialization, with key capabilities in respiratory diseases, particularly influenza. Biota has developed the in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Relenza is used to treat seasonal influenza. Biota's research outcomes have included nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, the Company has a partnership with Daiichi Sankyo for the development of second-generation influenza anti-virals. In March 2010, the Company completed acquisition of the antibacterial assets of MaxThera Inc.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watson W. Mark	Director	Jun 18 '24	Buy	0.68	20,000	13,578	78,125	Jun 20 06:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VXRT

Vaxart Inc

Upgrade your FINVIZ experience